ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Mi...(scular blockages 33% of patientstreated ...),Health

Date:9/28/2008

scular blockages, 33% of patients treated with microplasmin achieved reperfusion compared with 14% of placebo-treated patients. Due to the small number of patients in this study, neither of these end points were statistically significant. However, the study also showed that microplasmin-treated patients had a statistically significant improvement in the level of damage to the blood brain barrier compared to placebo-treated patients, measured using the marker of matrix metalloproteinase (MMP). MMP activation plays a crucial role in the pathogenesis of brain edema and hemorrhagic transformation after ischemic stroke.

Professor Vincent Thijs, Lead Principal Investigator of the trial, commenting on the results said, "I am delighted that we were able to present these interesting results at the World Stroke Congress. The results show that microplasmin is safe and generally well tolerated with no evidence of increased bleeding risk. Moreover, the results also support previous preclinical studies that have shown that microplasmin is able to lyse clots and may also have certain vascular protective properties."

Dr. Patrik De Haes, CEO of ThromboGenics, commenting on today's announcement said: "I am very pleased that we have been able to successfully conclude this study of microplasmin in patients with stroke. The results that have been reported show that the product is well tolerated and could potentially be of benefit in this indication of high medical need. However, as we have stated previously, our current view is that it only makes sense for ThromboGenics to move forward with the development of microplasmin for vascular indications in cooperation with a partner, given the costs and risks involved. We believe that by focusing on the development of microplasmin for eye disease, where we have already generated encouraging clinical data, and carefully utilizing our resources on the other opportunities in our pipeline, we will continue to generate a high return f
'/>"/>

SOURCE ThromboGenics NV Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
2. Indevus Announces Agreement With Teva to Develop Pagoclone for the Treatment of Stuttering
3. Clinton Global Initiative Announces BDs Commitment to Biamba Marie Mutombo Hospital
4. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
5. Chemstar Corporation Announces a New Powerful, One-Step Product That Effectively Controls Listeria, Salmonella, E. coli and Fly Larvae in Floor Drains
6. QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
7. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
8. Phosphagenics Announces Initiation of Phase 1 Clinical Trial in Humans for Its Transdermal Lidocaine
9. Napo Announces Positive Clinical Data Indicating Crofelemer, Could Effectively Treat Cholera
10. Encorium Announces the Initiation of a Strategic Partnership With Prologue Research After the Postponement of Negotiations Regarding Its Planned Acquisition; Strategic Reorganization and Cost Reduction Plan Initiated as Strategic Alternatives are Investig
11. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) Needle